Abstract
Background Activins are members of the TGFβ-superfamily implicated in the pathogenesis of several immuno-inflammatory disorders. Based on our previous studies demonstrating that over-expression of Activin-A in murine lung causes pathology sharing key features of COVID-19, we hypothesized that Activins and their natural inhibitor Follistatin might be particularly relevant to COVID-19 pathophysiology.
Methods Activin-A, Activin-B and Follistatin levels were retrospectively analyzed in 574 serum samples from 263 COVID-19 patients hospitalized in three independent centers, and compared with common demographic, clinical and laboratory parameters. Optimal-scaling with ridge-regression was used to screen variables and establish a prediction model.
Result The Activin/Follistatin-axis was significantly deregulated during the course of COVID-19, correlated with severity and independently associated with mortality. FACT-CLINYCoD, a novel disease scoring system, adding one point for each of Follistatin>6235pg/ml, Activin-A>591pg/ml, Activin-B>249pg/ml, CRP>10.3mg/dL, LDH>427U/L, Intensive Care Unit (ICU) admission, Neutrophil/Lymphocyte-Ratio>5.6, Years of Age>61, Comorbidities>1 and D-dimers>1097ng/ml, efficiently predicted fatal outcome in an initial cohort (AUC: 0.951±0.032, p<10−6). Two independent cohorts that were used for validation indicated comparable AUC (0.958, p=0.880 and 0.924, p=0.256, respectively).
Conclusions This study unravels strong link between Activin/Follistatin-axis and COVID-19 mortality and introduces FACT-CLINYCoD, a novel pathophysiology-based tool that allows dynamic prediction of disease outcome, supporting clinical decision making.
Competing Interest Statement
Potential conflicts of interest: Authors BK and AK are employees of Ansh Labs, which is the manufacturer of the ELISA kits used in this study. The rest of the authors declare no conflict of interest.
Clinical Trial
N/A
Funding Statement
Funding: General Secretariat of Research and Technology, Greece, Grants: CYTONET (T1EDK-00617) and EATRIS-GR (OPS5028091).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol design was approved by the Local Scientific and Ethics Committees and Institutional Review Boards of the University Hospital of Alexandroupolis (Ref. No. 803/23-09-2019 and Ref. No. 87/08-04-2020), AHEPA University Hospital of Thessaloniki (Ref. No. 1789/2020) and ATTIKON University Hospital of Athens (Ref. No. 487/3-9-2020). Patients' records were anonymized and de-identified prior to analysis so confidentiality and anonymity were assured.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Potential conflicts of interest: Authors BK and AK are employees of Ansh Labs, which is the manufacturer of the ELISA kits used in this study. The rest of the authors declare no conflict of interest.
Funding Support: This work was supported by grants from the General Secretariat of Research and Technology, Greece, CYTONET (T1EDK-00617) and EATRIS-GR (OPS5028091).
This version revised for the inclusion of a second independent validation cohort and the addition of the information regarding approvals from the Local Scientific and Ethics Committees and Institutional Review Boards of the relevant Institutions.
Data Availability
All data referred to in the manuscript are avaliable upon request.
